PH12017500447A1 - Triazole compounds as t-type calcium channel blockers - Google Patents

Triazole compounds as t-type calcium channel blockers

Info

Publication number
PH12017500447A1
PH12017500447A1 PH12017500447A PH12017500447A PH12017500447A1 PH 12017500447 A1 PH12017500447 A1 PH 12017500447A1 PH 12017500447 A PH12017500447 A PH 12017500447A PH 12017500447 A PH12017500447 A PH 12017500447A PH 12017500447 A1 PH12017500447 A1 PH 12017500447A1
Authority
PH
Philippines
Prior art keywords
channel blockers
calcium channel
type calcium
triazole compounds
compounds
Prior art date
Application number
PH12017500447A
Inventor
Olivier Bezencon
John Gatfield
Bibia Heidmann
Romain Siegrist
Simon Stamm
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of PH12017500447A1 publication Critical patent/PH12017500447A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
PH12017500447A 2014-09-15 2017-03-09 Triazole compounds as t-type calcium channel blockers PH12017500447A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2014069592 2014-09-15
PCT/EP2015/070934 WO2016041892A1 (en) 2014-09-15 2015-09-14 Triazole compounds as t-type calcium channel blockers

Publications (1)

Publication Number Publication Date
PH12017500447A1 true PH12017500447A1 (en) 2017-07-31

Family

ID=54106361

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017500447A PH12017500447A1 (en) 2014-09-15 2017-03-09 Triazole compounds as t-type calcium channel blockers

Country Status (16)

Country Link
US (1) US10246426B2 (en)
EP (1) EP3194374B1 (en)
JP (1) JP6500092B2 (en)
KR (1) KR102424750B1 (en)
CN (1) CN107074822B (en)
AU (1) AU2015317022B2 (en)
CA (1) CA2956816C (en)
CL (1) CL2017000616A1 (en)
EA (1) EA032873B1 (en)
ES (1) ES2693052T3 (en)
IL (1) IL251042A0 (en)
MX (1) MX367519B (en)
PH (1) PH12017500447A1 (en)
PL (1) PL3194374T3 (en)
SG (1) SG11201701998XA (en)
WO (1) WO2016041892A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015186056A1 (en) 2014-06-03 2015-12-10 Actelion Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
CA3046846A1 (en) 2016-12-16 2018-06-21 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
US10899695B2 (en) 2017-02-06 2021-01-26 Idorsia Pharmaceuticals Ltd Process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
UA126582C2 (en) 2017-07-05 2022-11-02 Ідорсія Фармасьютікалз Лтд Crystalline form of n-[1-(5-cyano-pyridin-2-ylmethyl)-1 h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
EP3996746A4 (en) 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
WO2023240205A1 (en) 2022-06-10 2023-12-14 Neurocrine Biosciences, Inc. Deuterated compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0766676B1 (en) 1994-06-24 2002-05-22 Euroceltique S.A. Compounds for inhibiting phosphodiesterase iv
ATE443698T1 (en) 1996-12-23 2009-10-15 Bristol Myers Squibb Pharma Co NITROGEN-CONTAINING HETEROCYCLES AS FACTOR XA INHIBITORS
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
EP1359911A2 (en) 2000-12-29 2003-11-12 Alteon, Inc. Method for treating fibrotic diseases or other indications ivc
WO2002053160A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ivb
AU2002363250A1 (en) 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
ES2295441T3 (en) 2001-12-18 2008-04-16 MERCK & CO., INC. MODULATORS OF PIRAZOL HETEROARIL REPLACED 5 METABOTROPIC RECEIVER OF GLUTAMATE.
DE60222698T2 (en) 2001-12-18 2008-06-19 Merck & Co., Inc. HETEROARYLSUBSTITUTED TRIAZOLE MODULATORS OF THE METABOTROPIC GLUTAMATAR RECEPTOR 5
SE0201658D0 (en) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
US20060194807A1 (en) 2003-04-03 2006-08-31 Cosford Nicholas D P Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
EP1613617A4 (en) 2003-04-04 2009-02-18 Merck & Co Inc Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
GB0328796D0 (en) 2003-12-12 2004-01-14 Biofocus Plc Compounds which interact with the G-protein coupled receptor family
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
GB0508463D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
CA2634147A1 (en) 2005-12-22 2007-06-28 Icagen, Inc. Calcium channel antagonists
BRPI0710487A2 (en) 2006-04-12 2012-06-05 Merck & Co Inc compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and method for treating or controlling epilepsy and pain and for treating or preventing a sleep disorder in a patient.
KR20090025358A (en) 2006-07-24 2009-03-10 에프. 호프만-라 로슈 아게 Pyrazoles as glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
WO2008085888A1 (en) 2007-01-05 2008-07-17 Arena Pharmaceuticals, Inc. G protein-coupled receptor and modulators thereof for the treatment of gaba-related neurological disorders including sleep-related disorders
JP5478488B2 (en) 2007-06-20 2014-04-23 メルク・シャープ・アンド・ドーム・コーポレーション JANUS kinase inhibitors
DE102007047738A1 (en) * 2007-10-05 2009-04-09 Merck Patent Gmbh imidazole derivatives
ES2446932T3 (en) 2007-10-08 2014-03-10 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their procedure and applications in medicine
CN101910133A (en) 2007-10-24 2010-12-08 默沙东公司 Heterocycle phenyl amide T-type calcium channel antagonists
CA2703471A1 (en) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Pyrazinyl amide t-type calcium channel antagonists
WO2009054983A1 (en) 2007-10-24 2009-04-30 Merck & Co., Inc. Heterocycle amide t-type calcium channel antagonists
JP2011516442A (en) 2008-04-04 2011-05-26 ビオマリン アイジーエー リミテッド Compounds for treating muscular dystrophy
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
CN102264737A (en) 2008-12-23 2011-11-30 雅培制药有限公司 Anti-viral compounds
US20120035237A1 (en) * 2009-04-24 2012-02-09 Diane Mary Coe Pyrazole and triazole carboxamides as crac chann el inhibitors
CA2761639C (en) * 2009-05-29 2016-06-07 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
WO2011022315A1 (en) 2009-08-19 2011-02-24 Merck Sharp & Dohme Corp. Pyrazinyl phenyl amide t-type calcium channel antagonists
US8987310B2 (en) 2009-10-30 2015-03-24 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
US20120264735A1 (en) 2009-12-21 2012-10-18 Jonathan Young Tyrosine kinase inhibitors
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
EP2402327B1 (en) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Acetamide compounds as glucokinase activators, their process and medicinal applications
KR20120063283A (en) 2010-12-07 2012-06-15 제일약품주식회사 Novel pyrazolopyridine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
AR096393A1 (en) 2013-05-23 2015-12-30 Bayer Cropscience Ag PESTICIDE HETEROCYCLIC COMPOUNDS
KR101685993B1 (en) 2014-05-15 2016-12-13 한국과학기술연구원 N-(pyrazolylmethyl)arylsulfonamide compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compositions comprising the same
WO2015186056A1 (en) * 2014-06-03 2015-12-10 Actelion Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
HUE058156T2 (en) 2015-01-30 2022-07-28 Neurocrine Biosciences Inc Substituted triazoles and methods relating thereto

Also Published As

Publication number Publication date
PL3194374T3 (en) 2019-01-31
EP3194374B1 (en) 2018-08-01
IL251042A0 (en) 2017-04-30
CN107074822A (en) 2017-08-18
KR20170052686A (en) 2017-05-12
MX367519B (en) 2019-08-26
BR112017005179A8 (en) 2017-12-26
CA2956816C (en) 2023-02-14
ES2693052T3 (en) 2018-12-07
WO2016041892A1 (en) 2016-03-24
US10246426B2 (en) 2019-04-02
EA032873B1 (en) 2019-07-31
AU2015317022B2 (en) 2020-01-16
EP3194374A1 (en) 2017-07-26
KR102424750B1 (en) 2022-07-22
MX2017003362A (en) 2017-06-28
CN107074822B (en) 2020-01-03
EA201790613A8 (en) 2018-10-31
SG11201701998XA (en) 2017-04-27
JP2017532309A (en) 2017-11-02
CL2017000616A1 (en) 2017-11-24
JP6500092B2 (en) 2019-04-10
AU2015317022A1 (en) 2017-04-27
US20180230109A1 (en) 2018-08-16
CA2956816A1 (en) 2016-03-24
EA201790613A1 (en) 2017-12-29
BR112017005179A2 (en) 2017-12-05

Similar Documents

Publication Publication Date Title
PH12016502230B1 (en) Pyrazole compounds and their use as t-type calcium channel blockers
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
MX2018006148A (en) Inhibitors of cxcr2.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2020004504A (en) Phenoxymethyl derivatives.
MX2020001278A (en) Synthesis of polycyclic-carbamoylpyridone compounds.
MX2018001430A (en) New bicyclic compounds as dual atx/ca inhibitors.
MX2018001890A (en) Bicyclic compounds as atx inhibitors.
PH12017500447A1 (en) Triazole compounds as t-type calcium channel blockers
MX2017006266A (en) Heteroaryl compounds as irak inhibitors and uses thereof.
MX2018002986A (en) Heteroaryl compounds as irak inhibitors and uses thereof.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
AU2014375265A1 (en) Novel pyrazolyl-heteroarylamides as pesticides
IN2015DN00960A (en)
MX2016016143A (en) Substituted [1,2,4]triazole compounds.
MX2017016619A (en) Pyrimidine derivatives as btk inhibitors and uses thereof.
EA201790687A1 (en) QUINOLINCARBOXAMIDE FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA
PH12016501997B1 (en) Cycloalkyl-linked diheterocycle derivatives
IN2014CH00151A (en)
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
PH12018500406A1 (en) Bicyclic compounds as atx inhibitors
PH12018500407A1 (en) New bicyclic compounds as dual atx/ca inhibitors
ZA201702615B (en) Triazole compounds as t-type calcium channel blockers
MX2018011117A (en) Crystalline form.